RYTM News and Press, Rhythm Pharmaceuticals Inc. From 03/08/19

Rhythm Pharmaceuticals (NASDAQ: RYTM ): Q4 GAAP EPS of -$0.74  misses by $0.16 . More news on: Rhythm Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

BOSTON, March 08, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today reported financial results and provided a busines...

BOSTON, March 04, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced that Keith Gottesdiener, M.D., Chief Ex...

NEW YORK, Feb. 07, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), Plug Power, Inc. (NASDAQ:...

Shares of Rhythm Pharmaceuticals ( RYTM ) have finished essentially flat, since my October 2017 article suggested that initial encouraging clinical data for drug candidate setmelanotide was just the beginning. On the other hand, the stock has performed admirably (up about 50%) since its $17...

Rhythm Pharma ( RYTM ) is a relatively underfollowed company with an ongoing phase 3 trial of lead (and only) drug setmelanotide in two obesity-related syndromes, Bardet-Biedl Syndrome ((BBS)) and Alström Syndrome, where enrollment will be completed in late 2019, and two other genetic obe...

Thinly traded Rhythm Pharmaceuticals ( RYTM +5.9% ) is up in early trade, albeit on only ~12,000 shares, following its announcement of 2019 milestones and updated clinical data on setmelanotide that will be presented on Thursday, January 10, at JPM19. More news on: Rhythm Pharmaceutica...

- Updated clinical data from Phase 2 basket studies evaluating setmelanotide in Bardet-Biedl Syndrome (BBS) show continued weight loss for additional two patients at longer-term follow-up – - Pivotal Phase 3 clinical trials in pro-opiomelanocortin (POMC) and leptin receptor (LE...

BOSTON, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced that company management will present a c...

NEW YORK, Oct. 17, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CURO Group Holdings Corp. (NYSE:CURO), BiondVax Pharmaceuticals Ltd. (NAS...